Aclaris Therapeutics Inc.

ACRS | NASDAQ

Price Alert Chart Builder DCF Calculator

$5.65

+$0.08 (+1.44%)

Sep 22, 2026, 2:47 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+1.44%

(1D)

Rating

Updated: Aug 22, 2026

33.5

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $788.47M

1D Range

5.50 5.71

52W Range

1.74 6.60

Valuation (TTM)

PE -9.60

PB 6.24

EV/EBITDA -9.14

Valuation (NTM)

Forward PE N/A

Forward PEG -0.75

Price Target $10.60

Cash Flow

FCF Yield -8.0%

SBC Adj. FCF Yield -9.5%

SBC Impact -18.8%

Margins

Gross Margin 95.6%

Operating Margin -1050.2%

FCF Margin -756.5%

Growth (CAGR)

Revenue 3Y | 5Y -35.9% | 4.4%

Dil EPS 3Y | 5Y 13.0% | 14.2%

FCF 3Y | 5Y 2.5% | 6.6%

Returns

ROA -42.1%

ROE -61.6%

ROIC -57.0%

Financial Health

Net Cash

$91.56M

Current Ratio 3.46

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inf...

Sector Healthcare

Industry Biotechnology

Employees 71

IPO Date Oct 5, 2015

Website www.aclaristx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$10

Upside

+76.99%

Buy (3)

Hold (0)

Sell (0)

Analyst Details ➞